Akèy › Leiomyosarkom
Etid klinik pou Leiomyosarkom ap rekrite nan Etazini
19 etid pou Leiomyosarkom ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX7 etid
- Boston, MA5 etid
- Chicago, IL4 etid
- Santa Monica, CA4 etid
- Aurora, CO3 etid
- Nashville, TN3 etid
- Ann Arbor, MI3 etid
- Rochester, MN3 etid
- Queens, NY3 etid
- Columbus, OH3 etid
- New York City, NY3 etid
- St. Louis, MO3 etid
Pa eta
- Colorado3 etid
- Florid3 etid
- Illinois4 etid
- Kalifòni9 etid
- Massachusetts5 etid
- Michigan4 etid
- Minnesota3 etid
- Missouri3 etid
- New York4 etid
- Ohio4 etid
- Tennessee4 etid
- Texas7 etid
- Virginia3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06498648Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT04031677Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT05711615A Study of Ivonescimab in People With Leiomyosarcoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT07516925STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT06975293NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Ap rekriteFaz 1/2
Jiska laj 30 · Tout sèks · Mizajou Aug 3, 2026 · NCT06239272A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT07633756Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT07628634AOH1996 for the Treatment of Refractory Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT05227326Localized Leiomyosarcoma Biomarker Protocol
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 2, 2026 · NCT04925089Metastatic Leiomyosarcoma Biomarker Protocol
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jun 24, 2026 · NCT05653388XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 18, 2026 · NCT06571734A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 11, 2026 · NCT06789172Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Feb 25, 2026 · NCT03016819Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
Ap rekriteFaz 2
Laj 65 a 100 · Tout sèks · Mizajou Feb 5, 2026 · NCT07125183Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2025 · NCT06528769Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Jun 13, 2025 · NCT06875700Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou May 29, 2025 · NCT01793168Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 24, 2025 · NCT04535271Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.